Stay updated on Selpercatinib in RET+ NSCLC Clinical Trial

Sign up to get notified when there's something new on the Selpercatinib in RET+ NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Selpercatinib in RET+ NSCLC Clinical Trial page

  1. Check
    6 days ago
    No Change Detected
  2. Check
    13 days ago
    Change Detected
    Summary
    Revision updated from v3.6.5 to v3.6.6, indicating a minor update to the record. This change does not modify the study text or data presented on the page.
    Difference
    0.0%
    Check dated 2026-09-01T18:24:54.000Z thumbnail image
  3. Check
    20 days ago
    Change Detected
    Summary
    A funding note '2019 ( U.S. NIH Grant/Contract )' was added to the study's identifiers, indicating NIH support for the LIBRETTO-431 trial. This broadens the funding attribution in the study record.
    Difference
    0.0%
    Check dated 2026-08-25T19:40:59.000Z thumbnail image
  4. Check
    27 days ago
    No Change Detected
  5. Check
    34 days ago
    Change Detected
    Summary
    Revision: v3.6.5 was applied, replacing the previous v3.6.4, indicating a backend or documentation update with no visible changes to the study content.
    Difference
    0.0%
    Check dated 2026-08-11T19:24:13.000Z thumbnail image
  6. Check
    56 days ago
    Change Detected
    Summary
    Revision updated from v3.6.3 to v3.6.4, representing a platform software upgrade. No study content, terminology, or essential page functionality appears to be altered by this change.
    Difference
    0.0%
    Check dated 2026-07-21T12:47:27.000Z thumbnail image
  7. Check
    77 days ago
    Change Detected
    Summary
    The page revision label was updated from Revision: v3.6.0 to Revision: v3.6.3, indicating a minor platform/content-management update.
    Difference
    0.0%
    Check dated 2026-06-30T01:06:54.000Z thumbnail image
  8. Check
    91 days ago
    Change Detected
    Summary
    The study record now shows that recruitment is no longer open to participants, indicating that enrollment is closed. New reader guidance sections were added (How to Read a Study Record, Common Questions, How to Join a Study) and the recruitment locations were updated to reflect Sariyer, Turkey, with a prior location removed, signaling changes to how participants can locate sites.
    Difference
    0.2%
    Check dated 2026-06-15T18:50:22.000Z thumbnail image

Stay in the know with updates to Selpercatinib in RET+ NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Selpercatinib in RET+ NSCLC Clinical Trial page.